Clinical trial · Observational
Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer
Using Functional Image and Circulating Molecular Markers to Predict Tumor Response and Lung Toxicity in Treatment of Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body and protect your normal tissue. This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and Ventilation/Perfusion Single Photon Emission Computerized Tomography (V/Q SPECT), before treatment and then again during treatment to see if it helps predict how well the treatment works for your cancer and how well your lung functions during treatment. A Computerized Tomography (CT) will also be performed along with both of these procedures to help the researchers see clearly where your cancer or your healthy lung is located. The researchers are also doing blood tests in this study to look for markers in your blood and to see if it helps them in determining your risk of developing side effects from radiation to the lungs. The researchers hope that this study will help them in the future to design radiation treatment plans that provide the best treatment for each individual patient.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Lung Cancer Imaging Patients
- description
- Adult patients (\>18 years of age)with histologically confirmed or clinically diagnosed lung cancer who require radiation therapy, with or without surgery and with or without chemotherapy.
Primary outcomes (1)
- measure
- The primary aim of this study is to investigate predictive models for long-term tumor control and late treatment lung toxicity by using FDG-PET-CT, V/Q SPECT-CT and blood tests during the course of radiation therapy.
- timeFrame
- During treatment with radiation at 40-50 Gy and up to 5 yrs after radiation completed
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) clinically diagnosed providing that FDG-PET is positive. * Stage I to III lung cancer requiring definitive irradiation with or without chemotherapy. * Patients with a locoregional tumor recurrence following surgery will be eligible provided they meet other eligibility criteria. * Patients must be 18 years of age or older. * Female patients with reproductive capability must be willing to use effective contraception * Patients must sign an informed consent form for study. Exclusion Criteria: * Malignant pleural or pericardial effusion. * Pregnancy * Lactation * Patients with diabetes mellitus, with uncontrolled fasting blood glucose level (above 200 mg/dl) * Inability to lie flat for the duration of PET/CT and V/Q SPECT (approximately 45 minutes for each study) * Prisoners are excluded from this study.
References
Publications (0)
Data not yet available